Review article:

NANOCARRIERS FOR DELIVERY OF siRNA AS GENE SILENCING MEDIATOR

Aideé Morales-Becerril, Liliana Aranda-Lara, Keila Isaac-Olivé, Blanca E. Ocampo-García, Enrique Morales-Ávila

Laboratorio de Toxicología y Farmacia, Facultad de Química, Universidad Autónoma del Estado de México, Toluca, Estado de México 50120, México

Laboratorio de Investigación en Teranóstica, Facultad de Medicina, Universidad Autónoma del Estado de México, Toluca, Estado de México 50180, México

Laboratorio Nacional de Investigación y Desarrollo de Radiofarmacos-CONACyT, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac, Estado de México 52750, México

* Corresponding author: Enrique Morales-Avila, Facultad de Química, Universidad Autónoma del Estado de México, Paseo Tollocan esq Paseo Colón S/N., Toluca, Estado de México. C.P. 50120, México. Tel. + (52) (722) 2 17 41 20, Fax. + (52) (722) 2 17 38 90, E-mail: enrimorafm@yahoo.com.mx or emoralesav@uaemex.mx

https://dx.doi.org/10.17179/excl2022-4975

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/).

ABSTRACT

The term nanocarrier refers to sub-micrometric particles of less than 100 nm, designed to transport, distribute, and release nanotechnology-based drug delivery systems. siRNA therapy is a novel strategy that has great utility for a variety of treatments, however naked siRNA delivery has not been an effective strategy, resulting in the necessary use of nanocarriers for delivery. This review aims to highlight the versatility of carriers based on smart drug delivery systems. The nanocarriers based on nanoparticles as siRNA DDS have provided a set of very attractive advantages related to improved physicochemical properties, such as high surface-to-volume ratio, versatility to package siRNA, provide a dual function to both protect extracellular barriers that lead to elimination and overcome intracellular barriers limiting cytosolic delivery, and possible chemical modifications on the nanoparticle surface to improve stability and targeting. Lipid and polymeric nanocarriers have proven to be stable, biocompatible, and effective in vitro, further exploration of the development of new nanocarriers is needed to obtain safe and biocompatible tools for effective therapy.

Keywords: siRNA, nanocarrier, drug delivery systems, nanomedicine

INTRODUCTION

The term nanocarrier refers to sub-micrometric particles less than 100 nm, designed to transport, distribute, and release molecules with biological activity. These drug delivery systems are based on nanotechnology and are identified as promising strategies used to overcome technical, biological and biopharmaceutical limitations, having among their advantages, the possibility of designing multifunctional drugs with high therapeutic efficacy, thanks to the possibility of increasing specificity and selectivity for cellular or molecular targets.
siRNA therapy is a novel strategy that has great utility in some chronic diseases, however, it has been observed that the delivery of naked siRNA has involved great difficulties, due to some of its physicochemical properties and its repercussions on biological behavior, such as its rapid degradation in biological fluids, its non-specific accumulation in tissues following systemic administration, its inability to penetrate cells by passive diffusion, and its short half-life of less than five minutes in plasma due to its susceptibility to nucleases (Sajid et al., 2020; Cullis and Hope, 2017).

The most prominent candidates for siRNA delivery are nanoparticle (NP) systems. siRNA can be incorporated into an NP formulation through covalent bonds with NP components or by electrostatic interactions with the NP surface, as acids in strongly negatively charged nuclei tend to form complexes. In addition, NP has been considered as specific and safe nanocarriers since they offer a set of advantages such as a high surface-to-volume ratio, a significant increase in bioavailability and a decrease in clearance of low bioavailable active ingredients (APIs), as well as their ability to preferentially accumulate on a selected target (see Figure 1) (Mainini and Eccles, 2020).

Nanocarriers based on nanoparticle formulations allow organ-specific targeting and provide a wide versatility to package siRNA with multifunctional performance due to their surface modifications, thus enabling the delivery of macromolecules via cellular and even transcellular pathways. In addition, it is suggested that nanoparticle systems can promote endosomal escape by different pathways such as the “proton sponge effect”, membrane fusion, membrane destabilization or induced swelling, thus preventing late endosome elimination in conjunction with API, which is very useful for siRNA delivery, since it enters cells by endocytosis like most nanoparticles (Lin et al., 2020; Ashrafizadeh et al., 2020; Kim et al., 2019a; Chevalier, 2019; Smith et al., 2019; Singh et al., 2018).

**Figure 1:** siRNA delivery systems can be constructed from a variety of materials with varying physicochemical features and biological behavior.
Interest in the development of siRNA nanocarriers began with gene therapy through the transfer of nucleic acids, including siRNA, microRNA (miRNA), short hairpin RNA (shRNA), antisense oligonucleotides (ASOs), aptamers, mRNA, plasmid DNA (pDNA), and CRISPR-Cas9. Exponential growth in the areas of molecular biology, pharmaceutical technology and materials science has enabled the design of effective pharmacological inhibitors, significant advantages regarding various pathological conditions, providing alternative to address gene overexpression for decades has become a promising therapeutic and nedosiran, fitusiran, teprasiran, cosdosiran of Phase 3 clinical trials, including protein. (mRNA) preventing its translation into a protein.

Small interfering RNA (siRNA) is a non-coding RNA-type oligonucleotide (nRNA; ~2 nm and ~13.5 kDa), its role in mediating post-transcriptional gene silencing has been widely studied and it has been established that binding to the RNA-Induced Silencing Complex (RISC, multi-protein complex) guides the specific degradation of messenger RNA (mRNA) preventing its translation into a protein. There are six siRNA drugs in late stages of Phase 3 clinical trials, including vutrisiran, nedosiran, fitusiran, teprasiran, cosdosiran, and tivanisiran. The use of siRNA in recent decades has become a promising therapeutic alternative to address gene overexpression for various pathological conditions, providing significant advantages regarding pharmacological inhibitors, highlighting its specific binding activity; meaning that siRNA can selectively bind to a target mRNA allowing the silencing of desired genes (Kokkinos et al., 2020; van den Brand et al., 2018; Sarkies and Miska, 2014; Lin et al., 2020).

In summary, there are 16 approved nucleic acid drugs: 9 ASO-based, 4 siRNA-based, 1 aptamer-based, and 2 mRNA-based (the latter being Tozanimersen developed by Pfizer/BioNTech and Elasomeran developed by Moderna, which were designed for the prevention of coronavirus-19 (COVID19), they were approved at the same time in 2020) (Paunovska et al., 2022; Zhuang and Cui 2021; Hodgson, 2021; Ferenchak et al., 2021).

NANOCARRIERS COMPOSED OF LIPID NANOPARTICLES

Lipids have the natural tendency to enhance cellular uptake of siRNA, with the added advantage of being very simple to formulate, have great versatility in their function, with diverse and programmable release profiles, just by modifying their lipid matrix and functionalizing molecules. Lipid nanocarriers are generally biodegradable, biocompatible, non-immunogenic or low immunogenic and have tolerable or low toxicity. However, in some cases, these nanocarriers are not completely inert, because some cationic lipids ( amphiphiles with quaternary ammonium head groups) can reduce mitosis in cells, form vacuoles in the cytoplasm, and cause detrimental effects on key cellular proteins such as protein kinase C. On the other hand, notable disadvantages include their limited stability, their relatively low capacity to load siRNA, and, occasionally, the possible interaction and breakdown of payloaded nucleic acids (Han et al., 2021; Inglut et al., 2020; Scheideler et al., 2020; Zatsepin et al., 2016; Tenchov et al., 2021).

RNA lipid nanocarriers are called lipoplex, which refers to systems composed of a combination of cationic lipids with nucleic acids, their formation consists of two steps, first, the cationic lipidic environment promotes electrostatic interactions, while the second step concerns the rearrangement and condensation of the lipoplex, forming structured self-assembly between lipids and phosphate groups from the siRNA main chain. The ge-
The geometry of lipids determines the phase structure (micellar, lamellar, cubic, and inverted hexagonal phase) according to the packing parameter, moreover, it is well known that the phase plays a significant role in physicochemical and biological behavior, determines digestibility, absorption pathway, distribution, uptake, and delivery mechanisms (see Figure 2). The most common lipid nanocarriers for siRNA delivery are micelles, liposomes, and lipid solids, but other lipid formulations are currently being studied and will later be discussed (Berger et al., 2021; Fairman et al., 2021; Kokkinos et al., 2020).

**Micelles**

Micelles are amphiphilic systems of small lipid vesicles with spherical shape, they have a hydrophobic core and a hydrophilic shell, they are produced by spontaneous self-assembly in aqueous media, their formation depends on amphiphile concentration, temperature, solvent, and size of hydrophobic/ hydrophilic domains, they can protect RNA/DNA and/or drugs in their micellar core, due to their small size ($\leq 100$ nm), they are applied for siRNA release, in most cases, they are conjugated with polymers to avoid binding to negatively charged serum proteins, also to prevent their aggregation, and to provide steric stabilization (Ojo et al., 2021).

---

**Figure 2:** a. Lipid packing parameters and phases (micellar, bilayer, hexagonal); b. Varieties of lipid phases (lamellar, sub-gel, gel, liquid crystalline, etc.); c. Lipid self-assembly aggregates (Koynova and Caffrey, 1998); d. Lipid nanocarriers for delivery
**Liposomes**

Liposomes are large, closed spherical vesicles constructed from a lipid bilayer, which could be classified according to their size (~0.025–5 μm) and their number of lipid bilayers (unilamellar or multilamellar vesicles), composed of different types of phospholipids, cholesterol and steroids bounding the hydrophilic core. Being formed by the self-assembly of amphiphilic molecules, the components are arranged so that they can be used as nanocarriers for both hydrophobic and hydrophilic components. These systems have a high degree of biocompatibility, degradability, efficacy, encapsulation capacity for plenty of APIs and ease of formulation. Liposomes serve as smart release systems in conjunction with various functionalizing agents, so they have been the standard for siRNA transfection (Ajeeshkumar et al., 2021; Aldosari et al., 2021; Majumder and Minko, 2021; Charbe et al., 2020; Bholakant et al., 2020).

**Solid lipids nanoparticles**

Other lipid nanocarriers are those composed of solid lipid nanoparticles (SLNs) with a size of around 100-200 nm, which are micellar vesicles formed by colloidal nanoparticles grouped in a lipid monolayer enclosing a solid, hydrophobic lipid core; they are formed after emulsion with a surfactant that stabilizes the lipid dispersion, their function is to prevent permeation and degradation of their components, they have the advantage of being highly biocompatible, moreover, they have good storage stability and provide the opportunity to carry out a sterilization and lyophilizing process if required, therefore, this type of nanocarrier can incorporate lipophilic or hydrophilic molecules such as siRNA following several strategies (Basha et al., 2021; Dhiman et al., 2021; Khalid et al., 2020; Yonezawa et al., 2020; Scheideler et al., 2020).

**Miscellaneous lipid nanoparticles for siRNA delivery**

The most commonly used lipid nanocarriers are liposomes, solid lipid NPs and nanostructured lipid carriers, among others, all of which have long-term physicochemical stability as nano-emulsions. Table 1 summarizes the reported lipid nanocarriers of nucleic acids. The droplet size range is 55 to 209 nm, with toxicity of less than 30 %, and in vitro gene knockdown ranging from 50 to 98 %. These nanocarriers are mainly designed for breast cancer therapy, and the predominant routes of administration are parenteral (intravenous (IV) or intratumoral (ITI) injection). Hybrid systems have been reported, composed with other types of nanoparticles such as polymeric ones, mainly forming liposomes that promote structural modifications with PEG to increase stability in plasma and avoid non-selective adhesion or, similarly, lipid nanocarriers with surface modifications with peptides, proteins, antibodies or aptamers (Herceptin or hyaluronic acid) that act as ligands to direct the nanocarriers to specific targets are observed (Rehman et al., 2020; Scheideler et al., 2020). The nanocarrier proposed by Ball et al. (2018) provides an example of a lipid nanocarrier designed for oral administration of siRNA, composed of a mixture of lipoid 3060, cholesterol, DSPC, and PEG 200-DMG with a size of about 140 nm, PDI of 0.12, and a ζ potential of ± 10 mV. Unfortunately, this nanocarrier did not effectively knockdown GAPDH in vitro and in vivo in Caco-2 cells and in the mouse model respectively, demonstrating that gene silencing efficiency may be affected mainly by pepsin, bile salts, and mucin concentrations, when the nanocarriers are administered orally since the nanocarriers are destabilized, altered, and trapped in the gastrointestinal (GI) tract environment.
Table 1: Nanocarriers composed of lipid nanoparticles

| Nanocarrier/ goal | Route* | Size (nm) | ζ (mV) | Nanocarrier toxicity | Gene silencing | Reference |
|-------------------|--------|-----------|--------|----------------------|----------------|-----------|
| Solid lipid nanoparticle / papilloma | ITI | 140.4 ± 12.9 | 43.9 ± 2.7 | KB cells: no data | MCL1: ~ 60% in vitro | Yu et al., 2012 |
| Components: retinol, DC-Chol, DPhPE, EDOPC, mPEG-DSPE, glyceryl trioleate, and PTX |
| Nanosphere / Myeloid Leukemia | IV | 55 | No data | K562 cells: < 30% | BCR-ABL: 90% in vitro | Jyotsana et al., 2019 |
| Components: ionizable cationic lipid and PEG-DMG |
| Micelle / colon cancer | ITI | 144.8 | 46.4 | C26 cells: <10% | Bcl-xl: ~75% Mcl-2: ~50% | Lu et al., 2019 |
| Liposome / cervical cancer | ITI | ~200 | No data | HeLa: non-toxic (0%) | Luc: 95% in vitro | Xu et al., 2013 |
| Components: G0-C14 (cationic lipid), PLGA-PEG, and cisplatin |
| Liposome / lung cancer | IV | 165.4 ± 1.7 | ~13 | H226 and A549 cells: <10% | Tumor inhibiting rate: ~75% in vivo | Qu et al., 2014 |
| Components: DPPC, DSPE-PEG, DDAB, and DTX |
| Liposome / ovarian cancer | ITI | 156.3 ± 6.7 | -3.1 ± 0.5 | SKOV-3 cells: ~5% | Bcl-2: ~85% P-gp: ~70% in vitro | He et al., 2015 |
| Components: DOTAP, DOPA, cholesterol, DSPE-PEG, and cisplatin |
| Liposome / lung cancer | IV | ~102 ± 2.6 | 22.5 ± 3.6 | NCI-H460 cells: no data | Luc: 70%–80% in vitro | Shi et al., 2017 |
| Components: DSPE-mPEG-AA, Metformin-cholesterol, DOPE, HA, and protamine |
| Liposome / cervical cancer | PR | 6.1 ± 0.3 (MLM)b | ~20 | HeLa cells: 10–20% | GFP: ~ 66% in vitro | Sánchez-Arribas et al., 2020 |
| Components: C3(C16His)2 (Gemini Cationic Lipid) and MOG |
| Liposome / breast cancer | IV | ~181.3 | ~36.6 | MCF-7 cells: ≤20% | Luc: ~ 98% in vitro | Hattori et al., 2020 |
| IV | 209 | ~32.7 | MCF-7 cells: 10–25% | Luc: ~ 95% in vitro |
| IV | 181 | ~27.4 | MCF-7 cells: <20% | Luc: ≥ 90% in vitro |
| Components: DOPE, DDAB, CS, and PEG (1) / DOPE, DOTAP, CS, and PEG (2) / DOPE, TC-1-12, CS, and PEG (3), respectively |
| Liposome / breast cancer | PR | 176 ± 54 | 28.1 ± 1.8 | SK-BR-3 cells: <20% | CDK4: 62-68% in vitro | Shin et al., 2020 |
| Components: DOPE, DC-Chol, HA, protamine, and PEG-thiolated Herceptin |
| Liposome / breast cancer and colon cancer | PR | 92.4 ± 24.5 | -33.6 ± 4.5 | MCF-7 and HT-29 cells: <20% | C-myc (MCF-7): ~ 95% in vitro | Habib et al., 2021 |
| PR | 126.8 ± 7.3 | -43.9 ± 5.4 | MCF-7 and HT-29 cells: <15% | C-myc (HT-29): ~ 90% in vitro |
| Components: MS09 and DOPE (1) / MS09 and Chol (2), respectively |
| Liposome / lung cancer | PR | ~170 | ~15 | A549 cells: <10% | PD-L1: ~70% in vitro | Gao et al., 2021b |
| Components: DOPC, Chol, and PEI-stearic acid |
Table 1 (cont.): Nanocarriers composed of lipid nanoparticles

| Nanocarrier/goal | Route\(^a\) | Size (nm) | ζ (mV) | Nanocarrier toxicity | Gene silencing | Reference |
|-----------------|-------------|-----------|--------|----------------------|----------------|-----------|
| Liposome/cancer | PR          | 122 ± 16  | 5.9 ± 0.9 | EA.hy 926 cells: non-toxic | GFP: ~55% in vitro | Ahmed et al., 2021b |
| PR              | 143 ± 12    | 8.9 ± 1.8 mV | EA.hy 926 cells: no data | GFP: ~50% in vitro |

Components: DOPC, Chol, and PEI- stearic acid

Components: DOPC, poloxamer (P407) and DMAPAP (PvcLDMAPAP) (1) / DOPC, poloxamer (P407) and PEI (PvcLPEI) (2), respectively

\(^a\) ITI: Intratumoral injection, IV: Intravenous injection; \(^b\): Multilamellar, PR: parenteral route

POLYMER NANOPARTICLE-BASED NANOCARRIERS

Polymersome micelles are supramolecular self-assemblies with different morphologies (spheres, discs, and worm-shaped assemblies), composed of amphiphilic synthetic macromolecules in which the individual block copolymers are generally linked by non-covalent interactions, solubilizing the API in their core, while their shell allows them to be suspended in the aqueous medium. Polymersome micelles are considered a good system siRNA delivery because they use the core-shell structure for delivery and are smaller in size (< 200 nm) and more efficient for cellular internalization than other polymeric nanocarriers, they also have a high loading efficiency, are versatile, stable under physiological conditions and can be divided into two categories: (1) micelles formed from direct binding of polymers via covalent (non-degradable) bonds to siRNA and (2) micelles formed from direct condensation of siRNA with amphiphilic polymer block (Wan et al., 2021; Ghezzi et al., 2021; Charbe et al., 2020).

Polymersomes

Polymersomes are characterized as spherical cavitory bodies with a bilayer membrane between 2-47 nm in size, morphologically similar to lipid-based vesicles but consisting of amphiphilic block copolymers. These nanocarriers show a lower permeability to water and can tolerate much more areal pressure before rupture. Consequently, they
Table 2: Nanocarriers composed of polymeric nanoparticles

| Nanocarrier/Treatment | Route | Size (nm) | ζ (mV) | Nanocarrier toxicity | Gene silencing | Reference |
|-----------------------|-------|-----------|--------|----------------------|---------------|-----------|
| Polymersome / lung cancer | PR | 100 | No data | A549 cells: non-toxic | Lamin A/C: ~40% in vitro | Kim et al., 2009 |

Components: PEG-polyalactic acid (OLA)

| Polymersome / breast cancer | PR | ~250 | No data | MCF10A cells: non-toxic | Orai3: ~85% in vitro | Pangburn et al., 2012 |

Components: OB, PR_b and GRGDSP

| Polymersome / stomach cancer | No data | 168.9 ± 8.3 | No data | MKN-45 and MKN28 cells: no data | Bcl-xL: 68-80% in vitro | Kim et al., 2013 |

Components: mPEG-b-PLA and DOX

| Polymersome / cancer | ITI | ~227 | 293T cells: no data | GFP: ~80% in vitro | Noh et al., 2011 |

Components: α-tocopherol oligochitosan (TCosome4K)

| Polymersome / hepatic cancer | PR | 232 | 11 | L02 cells: non-toxic | miR-429 (HCCLM3): ~80% in vitro | Chen et al., 2015 |

Components: PEO-b-PDPA-b-PAA, Antibody, EpCAM, Streptavidin, and DOX-HCl

| Polymersome / sundry cancers | PR | 173 ± 7 | Neutral | B16F10, MCF-7 and KB cells: <20% | Luc (B16F10): 31% in vitro | Gallon et al., 2015 |

Components: mPEG₄₃-plmHeMA₆₇-pGMA₃₆, tBocPEG₆₀-plmHeMA₃₀-pGMA₅₈, and folate-PEG₂₀-plm-HeMA₃₀-pGMA₅₈

| Polymersome / hepatic cancer | PR | 203 | 31.9 | HepG2 cells: no data | No data | Li et al., 2015 |

Components: PAsp(DIP)-b-Plys and DOX (N/P 2)

| Polymersome / lung cancer | IV | 101-175 | Neutral | A549 cells: non-toxic | PLK1: ~75% in vitro | Zou et al., 2017 |

Components: PEG-P(TMCDT)-PEI and cNGQ-PEG-P(TMCDT) (400 nM siRNA)

| Polymersome / cancer | SC | 462 | ~30 | L02 cells: ~10% | FAM: no data | Wang et al., 2018 |

Components: PEO-b-P(NIPAM-stat-CMA-stat-DEA) (37°C and 40 µg /mL)

| Polymersome / breast cancer | No data | 131.5-137.7 | No data | MCF-7cells: ~5% | P-gp: ~60% in vitro | Zheng et al., 2019 |

Components: PNIIPAM orthopyridyl disulfide, mercapto siRNA and DOX-HCl

| Polymersome / lung cancer | IV | 90 | Neutral | A549 cells: no data | PLK1: ~85% in vitro | Qiu et al., 2019 |

Components: PEG-b-PAPA-b-PLL and CPP33-PEG-bPAPA (400 nM siRNA)

IV: Intravenous injection, PR: parenteral route, SC: subcutaneous injection, ITI: intratumorally injection
are resistant, stable and are used to administer both hydrophilic and hydrophobic APIs, however, their slow release may sometimes be a disadvantage due to their membrane thickness. On the other hand, thanks to the characteristic self-assembly of amphiphilic block copolymers, they can maintain their well-defined structure in an aqueous media promoted by a thermodynamic phenomenon between non-covalent physical interactions. Due to the physicochemical versatility of polymersomes, their increased stability and improved payload retention, they are used for the delivery of nucleic acids and/or macromolecules for both in vitro and in vivo delivery (pDNA, AON, siRNA) (Scheerstra et al., 2022; Araste et al., 2021; Moulahoum et al., 2021; Iqbal et al., 2020).

Dendrimers

Dendrimers are a class of highly stable spherical nanoparticles with high biocompatibility and resistance to proteolytic digestion, macromolecules characterized by their symmetry and 3-D globular architecture, consisting of a central core, inner branches, and outer surface. Dendrimers have a well-defined shape, a highly monodisperse size, and a chemical homogeneity resulting from their repetitive branched pattern. In addition, they have significant advantages over linear polymers in that they have a higher loading capacity, a larger number of high-density surface functionalities that allow them to conjugate with other components. These nanocarriers called dendriplex, easily encapsulate siRNA and are optimal for delivery because their protonated amines induce an endosomal osmotic burst resulting in cytoplasmic accumulation of siRNA (Pishavar et al., 2021; Subhan et al., 2021; Yan et al., 2021; Bholakant et al., 2020).

Cyclodextrin polymers

Cyclodextrins (CD) are crystalline, homogeneous, non-hygroscopic substances with different sizes, belonging to the family of tricyclic oligosaccharides composed of glucose units, they are differentiated according to their number of units; αCD (6), βCD (7), and γCD (8), they have been used as excellent solubilizers and stabilizers thanks to their torus-like macro ring shape and their relatively hydrophobic cavity associated with an aqueous environment that allows them to form “host-guest” inclusion complexes, where the dissolved CD (host) allows energetically disadvantaged water molecules to move into their cavities with the “guest” molecule (ions, proteins, or oligonucleotides). Cyclodextrin polymers can be defined as molecules containing more than two covalently linked CD units, they are used to provide an alternative to conveniently deliver hydrophobic/hydrophilic molecules, thus, these systems are nanocarriers that could provide safe, effective, and targeted delivery of siRNA (Xu et al., 2021a; Pandey et al., 2022; Pandey, 2021; Mousazadeh et al., 2021; Petitjean et al., 2021; Liu et al., 2021b; Yao et al., 2019; Ceborska, 2017).

Miscellaneous polymeric nanocarriers for siRNA delivery

Some polymeric nanocarriers are shown in Table 3, where the outstanding use of polymers such as PEG, PCL, PEI, and PNIAPM is observed. At the same time, it is observed that polymeric nanocarriers are conjugated with ligands, such as peptides, folic acid, and hyaluronic acid, and even hybrid polymeric nanocarriers composed of inorganic nanoparticles are observed. In general, these nanocarriers have sizes ranging from 7 to 591 nm, toxicity of less than 50 %, and gene knockdown ranging from 20 and 90 % in vitro, and are mainly used for melanoma, administered by IV injection. Additionally, other nanocarriers designed for the oral administration of siRNA, proposed by He et al. (2020) are presented, these nanocarriers were composed of mannose-modified trimethyl chitosan-cysteine (MTC) and anionic cross linkers including TPP, HA, and Eudragit® S100, their properties were a size range between 120 and 225 nm and a ζ potential of 18-37 mV, they also
showed an effective \textit{in vitro} TNF-\(\alpha\) knock-down of 25-75 \% in Raw 264.7 cells and no significant toxicity (<10 \%). These results in simulated gastric fluid are due to mucoadhesive properties of the three functional groups (trimethyl, thiol, and mannose) of the nanocarrier that promote oral absorption and the use of Eudragit® S100 that does not dissolve the system down to a specific pH.

Table 3: Nanocarriers composed of miscellaneous polymeric nanoparticles

| Nanocarrier/Treatment | Route | Size (nm) | \(\zeta\) (mV) | Toxicity | Gene silencing | Reference |
|-----------------------|-------|-----------|---------------|----------|----------------|-----------|
| Micelle / melanoma    | PR    | 132.2 ± 2.6 | 29.3 ± 1.2 | MDA-MB-435 cells: 20\% | VEGF-85\% \textit{in vitro} | Zhu et al., 2010 |
| **Components:** PDMAEMA–PCL–PDMAEMA and PTX |
| Micelle / melanoma    | IV    | 103.4 ± 5.1 | 4.23 ± 0.51 | MDA-MB-435 cells: no data | MDR1: no data | Xiong and Lavasanifar, 2011 |
| **Components:** Acetal-PEO-b-PCL, polyamine, TAT, RGD, and DOX |
| Micelle / hepatic cancer | PR  | ~190 | 18.9 | Bel-7402 cells: <20\% | Bcl-2: >50\% \textit{in vitro} | Cao et al., 2011 |
| **Components:** PEI-PCL, FA-PEG-PGA, and DOX |
| Micelle / melanoma    | IV    | 50 | No data | MDA-MB-435 cells: no data | Ptk1: 32\% - 78\% \textit{in vitro} | Sun et al., 2011 |
| **Components:** mPEG-b-PCL-b-PPEEA and PTX |
| Micelle / breast cancer | IV  | 121.3 ± 1.9 | 20.48 ± 1.8 | MCF-7 cells: <10\% | Bcl-2: 32\% - 78\% \textit{in vitro} | Zheng et al., 2013 |
| **Components:** PEG-PLL-PLLLeu and DTX |
| Micelle / breast cancer | PR  | 243 ± 12.1 | 36.33 ± 4.5 | MCF-7/ADR: no data | P-gp: >75\% | Misra et al., 2014 |
| **Components:** PLGA, DMAB, PVA, TPGS, and DOX |
| Micelle / lung cancer | IV    | 43 | neutral | A549 cells: no data | GFP: ~45\% \textit{in vitro} | Zhu et al., 2014 |
| **Components:** PEG-pp-PEI-PE and PTX |
| Micelle / ovarian cancer | IV | 64 | 5.3 | SKOV3 cells: <30\% | Bcl-2: ~60 \% \textit{in vitro} | Chen et al., 2014 |
| **Components:** PEG-PAsp(AED)-PDPA and DOX |
| Micelle / breast cancer | IV | 80-140 | 16-36 | 4T1 cells: 27.1\% | Tumor inhibiting rate: 76.5\% \textit{in vivo} | Tang et al., 2015 |
| **Components:** PEI-PDHA, PEG-PDHA, and PTX |
| Micelle / ovarian cancer | IV | ~25 | No data | SKOV3-tr cells: non-toxic (0\%) | Survivin: 90 \% \textit{in vivo} | Salzano et al., 2015 |
| **Components:** PEG2000-PE and PTX |
| Micelle / hepatic cancer | ITI | ~200 | 20 | SMMC-7721 cells: ~25\% | VEGFA: ~50\% | Yuan et al., 2020 |
| **Components:** PEI with heptafluorobutyric anhydride |
| Micelle / hypopharyngeal carcinoma | PR | 120 | ~6 | FaDu cells: ~10\% | Luc: 40-50\% \textit{in vitro} | Fliervoet et al., 2020 |
| **Components:** PNIPAM-PEDMAEMA and PNIPAM-PED-PE-NIPAM (N/P5/37°C/500 nm) |
| Micelle / asthma | IN | 150–275 | 2.5 - 7.5 | 16-HBE cells: ~20\% | IL-4: <45\% \textit{in vitro} | Craparo et al., 2020 |
| **Components:** PHEA-g-PEG-g-bAPAE (35 \% DD bAPAE) / (p/p :10) |
| Micelle / melanoma | IV | 51.2 ± 1.3 | 5 ± 0.5 | B16-F10 cells: <20\% | RelA: >50\% \textit{in vivo} | Ibaraki et al., 2020 |
| **Components:** mPEG-PCL and functional peptide (CH2R2H2C) / (N/P 10) |
### Table 3 (cont.): Nanocarriers composed of miscellaneous polymeric nanoparticles

| Nanocarrier/Treatment | Route | Size (nm) | $\zeta$ (mV) | Toxicity | Gene silencing | Reference |
|-----------------------|-------|-----------|-------------|----------|----------------|-----------|
| Micelle / melanoma    | IV    | 326.1 ± 35.0 | -13         | MDA-MB-231 cells: <20% | PLK1: ~80% in vitro PLK1: 90% in vivo | Li et al., 2021a |
| **Components:** 4-MAPBA-NIPAM-Bis-Acridita-DNA (DPNF) and ATP |
| Dendrimer-based / glioblastoma | PR    | No data | No data | U87MG cells: nontoxic until 5.5 μg/mL | Luc: 75% in vitro | Kaneshiro and Lu, 2009 |
| **Components:** poly(L-lysine) G3, PEG-RGD, and DOX |
| Dendrimer-based / ovarian cancer | ITI   | 85       | 32         | SKOV-3 cells: nontoxic (0%) | Akt:50% in vitro | Kala et al., 2014 |
| **Components:** PANAM G6 and PTX |
| Dendrimer-based / ovarian cancer | PR    | 175.8 ± 1.04 | 4.55 ± 0.25 | A2780 ADR cells: <25% | P-gp: 40 % in vitro | Pan et al., 2019 |
| **Components:** PANAM G4-PEG2000-DOPE, PEG-DOPE, and DOX |
| Dendrimer based / glioblastoma | IV    | 200       | neutral    | U87MG cells: ~30% | VEGFA: ~25% in vitro | Bai et al., 2020 |
| **Components:** Oligo-spermine-imidazole-diimine, PANAM G6, and tri-block copolymer |
| Dendrimer-based / prostatic cancer | IV    | 591.1 ± 6.6 | -1.40 ± 0.14 | PC-3 cells: Non-toxic (0%) | Luc: ~80 % in vitro | Noske et al., 2020 |
| **Components:** Tyrosine-Modified PPI (PPI-G4-Y) |
| Cyclodextrin polymers-based / papilloma | IV    | ~150      | ~7.5       | KB cells: nontoxic (0%) | Bcl-2: 20% GFP: 88% in vitro | Wen et al., 2020 |
| **Components:** β-CD-SS-pDMAEMA and Ad-PEG-FA |
| Nanocapsule / papilloma | ITI   | ~7        | neutral    | KB cells: <50% | EG5 (KSP): ~80 % in vitro | Lee et al., 2016 |
| **Components:** Succinoyl tetraethylene pentaamine, o-amino acids, PEG, MTX, and Inf7 peptide |
| Nanocapsule / glioblastoma | IV    | 25.6      | neutral    | U87MG Cells: nontoxic (0%) | PLK1: 66 % in vitro | Zou et al., 2020 |
| **Components:** Acrylate guanidine, N,N′-bis(acryloyl) cystamine, PEG and Angiopep-2 |

**Note:** ITI: Intratumoral injection, IV: Intravenous injection, IN: Intranasal, PR: parenteral route

### NANOCARRIERS COMPOSED OF INORGANIC NANOPARTICLES

Inorganic nanoparticles (INPs) for siRNA delivery are generally composed of different types such as metallic nanoparticles, where gold nanoparticles stand out, super-magnetic nanoparticles, mainly iron oxides, semiconductor nanoparticles such as quantum dots, and ceramic nanoparticles, mainly mesoporous silica. INPs have emerged as valuable...
building blocks with continuous breakthroughs, particularly in their optical, electronic, magnetic, and catalytic properties, making them capable of detecting, diagnosing, and treating many diseases, and thus have numerous biomedical applications, including siRNA therapy. Moreover, INPs are synthesized through a variety of methods, creating extremely organized three-dimensional structures which can be modified with ligands to improve their affinity, they also have fairly attractive advantages such as precise control of nanocarrier size, high loading efficiency, control of API release, tunable surface properties, inertia, high stability, good reproducibility, easy cellular absorption, long useful life, and very attractive physical properties, making them prominent as theragnostic agents and recently as functional nanocarriers for siRNA and chemotherapeutic agents (Lins et al., 2021; Torres-Vanegas et al., 2021; Khan et al., 2020; Khurana et al., 2019).

For effective siRNA delivery, it is essential that these nanocarriers have external functionalization. Thus, INPs can form a coordination network between siRNA and organic nanoparticles, which generally increase their efficiency by improving their biocompatibility and protecting them from oxidation. In addition, INPs can be anchored to siRNA by physical adsorption, covalent coupling, or metal-ligand interactions. This versatility in incorporating siRNA has caused some of these nanocarriers to reach the advanced stage for clinical development, although most of them are still in the early stages (Zou et al., 2021; Yau et al., 2021; Jiang and Thayumanavan, 2020; Charbe et al., 2020).

**Metal-based nanoparticles: AuNPs**

Among the nanocarriers composed of metallic nanoparticles, gold nanoparticles (AuNP) are commonly used since they have unique biochemical properties and can be created with a wide versatility of shape, size (~15-50 nm using the Turkevich method), and tunable surface charges, they also have good properties such as non-toxicity, biocompatibility and can be easily adsorbed to the surface of APIs or can bind through covalent thiol bonds. In addition, these nanocarriers can induce a controlled release through different strategies and offer unique optical and electronic properties due to their strong localized surface plasmon resonance (LSPR). Gold nanoparticles coated with polymers or conjugated to another molecular compound have been extensively studied as siRNA delivery systems, since they have successfully demonstrated to be effective in gene knockdown, have no detectable off-target effects, and also provide a photothermal therapeutic effect as a secondary function, making them even more attractive as nanocarriers (Pylaev et al., 2021; Aghamiri et al., 2021; Moore and Chow, 2021; Gumala and Sutriyo, 2021).

**Base-magnetic nanoparticles: SPIOs**

Magnetic nanoparticles (MNs) are a new type of magnetic nanocrystals composed of iron, nickel, cobalt, or magnesium. Iron oxides (Fe$_3$O$_4$ or Fe$_2$O$_3$) are the most important MNP because they can produce strong paramagnetism, even superparamagnetism (SPIO, iron oxides with a diameter <50 nm) and are also safer than cobalt or nickel, which are reported to be more toxic. SPIOs possess advantages such as uniform size, large surface areas, high surface-to-volume ratio, a rapid transfection process and efficient biodegradability. In addition, SPIOs can provide target-oriented delivery because they interact with external magnetic fields (EMF) that allow them to be lead to target sites, even to hard-to-transfect and non-permissive cells, at the same time, they can provide molecular imaging and a magnetocaloric effect which can indirectly kill tumor cells, which is why these nanocarriers are used for siRNA delivery. These nanocarriers are highly efficient for releasing siRNA, thanks to magnetofection, a technique to enhance the efficiency of transfection of nucleic acid with EMF, but require improvements in their colloidal stability, so they usually have surface modifications using polymeric cross linkers that encapsulate these
Semiconductor-based nanoparticles: QDs

Quantum dots (QDs) are colloidal semiconductor nanocrystals with sizes <10 nm, in general, their structure consists of a core and shell, composed of group II-VI elements (CdTe, ZnS, and CdSe), group III-IV elements (InAs and InP) or group III-IV elements IV-VI (CS, CS, PbS, and PbSe). They can be classified into three main types: (1) according to their composition/structure: core-type (formed with a single component), core-shell type (core encapsulated by a semiconducting substance) and alloyed (formed with two semiconducting materials), (2) according to the material used for their preparation: semiconducting QDs and carbon/graphene QDs and (3) according to their size; large (5-6 nm) and small (2-3 nm). QDs have optical properties, absorbance and photoluminescence depending on size, shape, composition and composition/structure. They can be functionalized with “molecular gates” and have external stimuli to allow charge delivery to be triggered. They can be functionalized with cationic polymers to enable electrostatic interactions with siRNA. Moreover, they can be functionalized with “molecular gates” and have external stimuli to allow charge delivery to be triggered (Gao et al., 2021a; Yau et al., 2021; García-Fernández et al., 2021; Taleghani et al., 2021; Lins et al., 2021).

Miscellaneous inorganic nanocarriers for siRNA delivery

To conclude this classification, Table 4 shows some examples of inorganic nanocarriers, where it is observed that Au-NPs (metallic nanoparticles) are the predominant INPs formulated, furthermore, all these nanocarriers are hybrid systems mainly with polymeric nanoparticles, also have properties such as size around 60-278 nm, toxicity less than 40 %, and gene knockdown in a range of 47-90 % in vitro. On the other hand, they are mainly used for breast cancer, administered by IV injection. Finally, nanocarriers designed for oral administration of siRNA are presented, proposed by Hosseini, et al. (2020) which were capsules composed of freeze-dried calcium phosphate- polyethylene glycol nanoparticles (CaP-PEG) and trehalose nanoparticles with an outer layer of Eudragit® L100 (EL), chitosan (CS), cellulose acetate phthalate (CAP), hydroxypropyl methylcellulose (HPMC) or/and polyvinyl alcohol (PVA) as an enteric coating. These nanocarriers had a size range of 45 and 65 nm, PDI of 0.16-0.40, potential ζ of 16-18 mV, EGFP knockdown of 21-43 % in vitro in HeLa cells, and significant toxicity of around 50-20 % attributed to some polymers used as mucoadhesive excipients.

Ceramic-based nanoparticles: MSNs

Ceramic nanoparticles are a relatively new type of porous inorganic nanoparticles for siRNA delivery, composed of silica, titanium oxide, calcium phosphate and alumina. These ceramic nanoparticles provide a tunable nanocarrier in both pore diameter (2-50 nm) and pore volume (> 0.9 cm³/g), as well as surface functionalization capability, high surface area, good biocompatibility, degradability, high loading capacity and chemical inertness. Mesoporous silica nanoparticles (MSNs) are the most relevant ceramic nanoparticles for siRNA delivery, having hundreds of empty channels that assemble into two- or three-dimensional porous structures, where they can load APIs such as siRNA. On the other hand, they are protonated by amination or coating with cationic polymers to enable electrostatic interactions with siRNA. Moreover, they can be functionalized with “molecular gates” and have external stimuli to allow charge delivery to be triggered (Gao et al., 2021a; Yau et al., 2021; García-Fernández et al., 2021; Taleghani et al., 2021; Lins et al., 2021).
Table 4: Nanocarriers composed of inorganic nanoparticles

| Nanocarrier                                      | Route | Size (nm) | ζ (mV) | Nanocarrier toxicity | Gene silencing | Reference          |
|-------------------------------------------------|-------|-----------|--------|----------------------|---------------|--------------------|
| Magnetic nanoparticles-base / breast cancer     | PR    | 197 ± 16  | ~7.8 ± 0.39 | MCF-7 cells: < 20 % | No data       | Amani et al., 2021 |
| Components: PLA-CS-spermine, PLA-PEG-Fa, PLA-PEG-17 peptide, OA-Fe₃O₄ and PTX |       |           |        |                      |               |                    |
| Ceramic nanoparticles-base / ovarian cancer      | PR    | ~91       | No data | A2780/AD: < 5 %      | Bcl-2: 80% in vitro | Chen et al., 2009 |
| Components: MSN, PANAM G2, and DOX              |       |           |        |                      |               |                    |
| Ceramic nanoparticles-base / endocervical adenocarcinoma | ITI   | 278       | ~7.3   | KB-V1 cells: ~40 %   | P-gp: 80-90% in vitro | Meng et al., 2010 |
| Components: MSN, PANAM G2, and DOX              |       |           |        |                      |               |                    |
| Ceramic nanoparticles-base / oral cancer         | ITI   | 170 ± 3.8 | 34.7 ± 0.9 | KBV cells: ~20 %    | MDR1: ~70% in vitro | Wang et al., 2017 |
| Components: MSN, PANAM G2, and DOX              |       |           |        |                      |               |                    |
| Semiconductor nanoparticles-base / breast cancer | IV    | 171.7 ± 4 | ~2.7 ± 0.6 | MDA-MB-231 cells: < 20 % | Bcl-2: > 80% in vitro | Kim et al., 2019b |
| Components: Cationic lipid, CdSe/ZnS (QDs), DSPE-mPEG and aptamer |       |           |        |                      |               |                    |
| Semiconductor nanoparticles-base / hepatic cancer | PR    | 83 ± 3    | >30    | SK-Hep1 cells: < 20 % | IL-8: ~63% in vitro | Cao et al., 2019  |
| Components: PCL- PDEM and CdSe/ZnS (QDs)        |       |           |        |                      |               |                    |
| Metallic nanoparticles-base / breast cancer      | IT    | 60 - 120  | 20 - 30 | MDA-MB-231 cells: 20 - 40% | EGFP-Luc: 50 - 80% in vitro | Taschauer et al., 2020 |
| Components: Au-NP y LPEI (1) / Au-NP y LPEI-PEG |       |           |        |                      |               |                    |
| Metallic nanoparticles-base / melanoma           | PR    | 187 - 228 | 15-20  | B16-F10 cells: < 20 % | PD-L1: 47% in vitro | Xue et al., 2021b |
| Components: Au-NP, PANAM-G5, mPEG-SCM, and fluorescamine |       |           |        |                      |               |                    |
| Metallic nanoparticles-base / lung cancer        | PR    | 86 ± 4    | 33 ± 3 | H1299 cells: < 5 %   | GFP: ~70% in vitro | Shaabani et al., 2021 |
| Components: AuNP and chitosan                   |       |           |        |                      |               |                    |
| Metallic nanoparticles-base / breast cancer      | IV    | 128       | ~16    | MCF-7 cells: < 5 %   | PLK1: 83% in vitro | Xue et al., 2021a |
| Components: Au-NP, ADC and Aptamer-YTDB         |       |           |        |                      |               |                    |
| Metallic nanoparticles-base / melanoma           | IV    | < 100     | ~2     | B16-F10 cells: < 10 % | Bcl-2: > 75% in vitro | Qiao et al., 2021 |
| Components: CTND-NP (copper complex) and PEI-PEG-FPBA |       |           |        |                      |               |                    |

**SUPPLEMENTARY PERSPECTIVE FOR NANOCARRIER DEVELOPMENT**

The success of siRNA-based therapeutics depends largely on their delivery system, thus requiring the use of nanocarriers that are at least: (i) biocompatible, biodegradable and non-immunogenic/non-toxic, (ii) non-sensitive to serum nucleases during transit through systemic circulation, (iii) specific for target cells while avoiding other tissues, and (iv) able to enter the cell membrane, the cellular environment and the endosomal pathway (Ge et al., 2021; Tenchov et al., 2021; Sharma et al., 2020; Mahmodi Chalbatani et al., 2019).
The foregoing nanocarriers showed propitious characteristics conducive to siRNA delivery, in general, it was observed that almost all of them are designed for IV administration, regardless of the target. Although IV administration allows 100% bioavailability of the API, it also had several limitations related to the invasiveness of the API administration process (pain at the injection site, patient discomfort, allergic reactions, scarring, etc.), this aspect should be considered especially for the treatment of chronic degenerative diseases such as cancer, which is one of the main approaches for the use of siRNA as a treatment and/or adjuvant, hence it is necessary that the development of nanocarriers also focuses on an oral administration of siRNA. In addition, this kind of administration can represent a potent modality for treating many gastrointestinal diseases such as inflammatory bowel disease (IBD), irritable bowel syndrome, and colon cancer, without adverse systemic effects (Tran and Park, 2021; El-Mayta et al., 2021; Kanugo and Misra, 2020).

It is well known that oral administration requires several efforts to deliver APIs, even more than parenteral administration (see Figure 3), since it is a complex process that can be affected by different factors such as physiological and cellular barriers, in particular, it was shown in some studies that naked siRNA can withstand gastric challenges for one hour at physiological temperature, but is inevitably degraded by nucleases, thus siRNA necessarily needs a nanocarrier that can avoid enzymatic digestion, overcome GI mucus barriers, and facilitate their delivery into target cells (Rehman et al., 2021; Ruiz-Picazo et al., 2021).

Some nanocarriers have been studied for oral siRNA administration; these nanocarriers are mainly composed of polymers and lipids. An example of oral administration was proposed by (Wang et al., 2021), they formed a lipoplex with folic acid-conjugated ginger-derived lipid and siRNA. Although polymers are good absorption enhancers (~bioavailability) and have benefits such as controlled drug release, they cannot provide a satisfactory solution due to their associated toxicities, so lipid-based drug delivery systems (LBDDS) have been frequently proposed in recent years. These nanocarriers have advantages such as low toxicity, low cost, affordable scale-up manufacture, high biocompatibility, high drug loading efficiency and recruit a range of lipid digestion pathways in the GI tract that play a decisive role in the drug absorption process (Ashkar et al., 2022; Plaza-Oliver et al., 2021; Zu et al., 2021; Tran et al., 2018).

![Figure 3: Advantage and disadvantage in oral and intravenous route for siRNA delivery, (Antimisiaris et al., 2021; Fumoto et al., 2021; van den Berg et al., 2021; Lorscheider et al., 2021; Hanna and Mayden, 2021)](image-url)
LBDDS can be classified into three types, previously mentioned two types: vesicular systems (micelles and liposomes) and solid lipid systems, the last type is an emulsion system, which is a novel approach for oral siRNA administration, especially the self-nanoemulsifying drug delivery system (SNEDDS). This system is composed of dissolved API, long and/or medium-chain triglyceride oils, high concentrations of non-ionic surfactants with HLB>12, and co-solvents to reduce interface between the oil and the aqueous medium, spontaneously forming fine oil-in-water nanoemulsions (o/w) in situ in the GI tract thanks to the stomach and small intestine motility (peristalsis) and the aqueous medium of the GI fluids, in a process called self-nanoemulsion (Dalal et al., 2021; Xu, et al., 2021b; Morakul, 2020; Sokkula and Gande, 2020; Knaub et al., 2019; Krstić et al., 2018; Cherniakov et al., 2015).

SNEDDS is an ideally isotropic and thermodynamically stable mixture, with droplet sizes below 200 nm thus having a large interfacial surface area for dispersion into the GI fluid, it is mainly designed to increase the solubility and permeability of APIs with lipophilic characteristics, however it has recently started to be used to improve the oral administration of hydrophilic macromolecules such as siRNA (nucleic acids), in such a way that the rate of drug dissolution, its absorption, digestion, and bioavailability can be improved. In addition, SNEDDS has a high drug loading capacity, is easy to manufacture and scale-up, it has good kinetic stability after dispersion in an aqueous medium, requiring a minimum amount of energy for dispersion and preparation, it has high physical stability during storage, decreases the first-pass effect and enhances penetration of highly lipophilic APIs into the intestinal membrane through the recruitment of intestinal lymphatic transport (Okonogi et al., 2021; Jain et al., 2021; Mehanna and Mneimneh 2020; Buya et al., 2020; Cardona et al., 2019; Gilani et al., 2019; Ng and Rogers, 2019; Rehman et al., 2017).

The main strategy for incorporating nucleic acids into SNEDDS includes reducing their hydrophilicity by pairing hydrophobic ions, this method is based on replacing the negatively charged counterions with positively charged surfactants or cationic lipids. The first work on this was presented by (Hauptstein et al., 2015), where pDNA complexes were formed using 5 different cationic components highlighting the use of cetrimide. These complexes were properly dissolved in SNEDDS thus the pDNA was successfully incorporated, obtaining a nanocarrier with an effect against enzymatic degradation and a good transfection efficiency of HEK-293 cells. Furthermore, Mahmood et al. (2016) presented a similar work based on pDNA-cetrimide, where the transfection efficiency of SNEDDS was improved by the incorporation of a cell-penetrating peptide (TAT-OL). Finally, the most recent work, to our knowledge, was presented by Kubackova et al. (2021) where SEDDS loaded with oligonucleotide (OND)-DDAB or DOTAP complexes were prepared and characterized using the hydrophobic ion pairing technique. This nanocarrier was a viable delivery system across the Caco-2 monolayer and was protected OND in the GI tract.

**CONCLUSIONS**

The use of siRNA as a mediator of gene silencing is a novel alternative for the treatment of various diseases, its advantages over traditional RNA delivery make it a suitable tool for the improvement of the bioavailability of a therapeutic effect. As a result, a wide range of nanocarriers for the transport and delivery of siRNA has been developed, however, only a few of them are in clinical trials.

The classification of nanocarriers outlined in this review is a suggestion, which considers the nature (organic and inorganic) of single ingredients, their chemical structure (lipids and polymers), and the shape of the nanocarrier (liposomes/polymersomes and micelles). However, almost all nanocarriers are hybrid
systems and should not be limited to a single classification; a relevant example of this are inorganic nanocarriers, which are generally composed of siRNA complexes with organic nanoparticles.

These nanocarriers have proven to be stable, biocompatible, and effective in vitro, but only very few are designed for oral administration of siRNA. This approach has emerged to offer enhanced nanocarriers that can satisfy different needs, such as a targeted treatment for gastrointestinal diseases and nanocarriers that may facilitate adherence to treatments and do not affect the patients’ quality of life. Therefore, there is a need to further explore the development of nanocarriers to obtain safe, biocompatible, and suitable biopharmaceutical tools that allow the enhancement of the absorption and targeting of siRNA for effective therapeutic alternatives.

Declaration of competing interests

The authors declare no conflict of interest.

Acknowledgments

The authors would like to acknowledge the financial support received from the National Council for Science and Technology (CONACyT, Mexico) through the grant: CONACyT-CF 2019-263379. This work was carried out as part of the activities of the National Laboratory for the Research and Development of Radiopharmaceuticals (LANIDER-CONACyT; Mexico). The authors also appreciate the graduate student scholarship granted to Aideé Morales-Becerril through the National Quality Postgraduate Program (PNPC; CONACyT, Mexico). She is a graduate student from the M.D. program in Science and Pharmaceutical Technology at UAEMex.

REFERENCES

Aghamiri S, Raee P, Talaei S, Mohammadi-Yeganeh S, Bayat S, Rezaee D, et al. Nonviral siRNA delivery systems for pancreatic cancer therapy. Biotechnol Bioeng. 2021;118:3669–90.

Ahmed A, Sarwar S, Hu Y, Munir MU, Nisar MF, Ikram F, et al. Surface-modified polymeric nanoparticles for drug delivery to cancer cells. Expert Opin Drug Deliv. 2021a;18(1):1–24.

Ahmed S, Salmon H, Distasio N, Doan H, Scherman D, Alhareth K, et al. Viscous core liposomes increase siRNA encapsulation and provides gene inhibition when slightly positively charged. Pharmaceutics. 2021b;13(4):479.

Ajeezhkumar KK, Aneesh PA, Raju N, Suseela M, Ravishankar CN, Benjakul S. Advancements in liposome technology: Preparation techniques and applications in food, functional foods, and bioactive delivery: A review. Compr Rev Food Sci Food Saf. 2021;20:1280–306.

Aldosari BN, Alfaighi IM, Almursheidi AS. Lipid nanoparticles as delivery systems for RNA-based vaccines. Pharmaceutics. 2021;13(2):206.

Amani A, Dustparast M, Noruzpour M, Zakaria RA, Ebrahimi HA. Design and in vitro characterization of green synthesized magnetic nanoparticles conjugated with multitargeted poly lactic acid copolymers for co-delivery of siRNA and paclitaxel. Eur J Pharm Sci. 2021;167:106007.

Antimisiaris SG, Marazioti A, Kannavou M, Natsaridis E, Gkartziou F, Kogkos G, et al. Overcoming barriers by local drug delivery with liposomes. Adv Drug Deliv Rev. 2021;174:53–86.

Araste F, Aliabadi A, Abnous K, Taghdisi SM, Ramezani M, Alibolandi M. Self-assembled polymeric vesicles: Focus on polymersomes in cancer treatment. J Control Release. 2021;330:502–28.

Ashkar A, Sosnik A, Davidovich-Pinhas M. Structured edible lipid-based particle systems for oral drug-delivery. Biotechnol Adv. 2022;54:107789.

Ashrafizadeh M, Hushima N, Rahmani Moghadam E, Zarrin V, Hosseinzadeh Kashani S, Bokaie S, et al. Progress in delivery of siRNA-based therapeutics employing nano-vehicles for treatment of prostate cancer. Bioengineering. 2020;7(3):91.

Bai G, Xue T, Dong X, Chinta UK, Fong J, Jin T, et al. Assembling structurally customizable synthetic carriers of siRNA through thermodynamically self-regulated process. Asian J Pharm Sci. 2020;15:356–64.

Ball RL, Bajaj P, Whitehead KA. Oral delivery of siRNA lipid nanoparticles: Fate in the GI tract. Sci Rep. 2018;8(1):2178.

Basha SK, Dhandayuthabani R, Muzammil MS, Kumar VS. Solid lipid nanoparticles for oral drug delivery. Mater Today Proc. 2021;36:313–24.
Bassetto M, Sen M, Poulhes F, Arango-Gonzalez B, Bonvin E, Sapat C, et al. New method for efficient siRNA delivery in retina explants: reverse magnetofection. Bioconjug Chem. 2021;32:1078–93.

Berger M, Lechanteur A, Evrard B, Piel G. Innovative lipoxepoxides formulations with enhanced siRNA efficacy for cancer treatment: Where are we now? Int J Pharm. 2021;605:120851.

Bholakant R, Qian H, Zhang J, Huang X, Huang D, Feijen J, et al. Recent advances of polycationic siRNA vectors for cancer therapy. Biomacromolecules. 2020; 21:2966–82.

Buya AB, Beloqui A, Memvanga PB, Préat V. Self-emulsifying drug-delivery systems: from the development to the current applications and challenges in oral drug delivery. Pharmaceutics. 2020;12(12): 1194.

Cao N, Cheng D, Zou S, Ai H, Gao J, Shuai X. The synergetic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells. Biomaterials. 2011;32:2222–32.

Cao Z, Xiao H, Li L, Liu M, Lin G, Zhai P, et al. The codelivery of siRNA and QDs by pH-responsive micelle for hepatoma cancer cells. Front Pharmacol. 2019;10:1194.

Cardona MI, Nguyen Le N-M, Zaichik S, Aragón DM, Bernkop-Schnürch A. Development and in vitro characterization of an oral self-emulsifying delivery system (SEDDS) for rutin fatty ester with high mucus permeating properties. Int J Pharm. 2019;562:180–6.

Castro E, Kumar A. Nanoparticles in drug delivery systems. In: Kumar A, Mansour HM, Friedman A, Blough ER (eds): Nanomedicine in drug delivery (pp 1-22). Boca Raton, FL: CRC Press, 2013.

Castro KC de, Costa JM, Campos MGN. Drug-loaded polymeric nanoparticles: a review. Int J Polym Mater Polym Biomater. 2022;71(1):1–13.

Ceborska M. Folate appended cyclodextrins for drug, DNA, and siRNA delivery. Eur J Pharm Biopharm. 2017;120:133–45.

Charbe NB, Amnker ND, Ramesh B, Tambuvala MM, Bakshi HA, Aljabali AAA, et al. Small interfering RNA for cancer treatment: overcoming hurdles in delivery. Acta Pharm Sin B. 2020;10:2075-109.

Chen AM, Zhang M, Wei D, Stueber D, Taratula O, Minko T, et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small. 2009;5(23):2673–7.

Chen J, Liu Q, Xiao J, Du J. EpCAM-antibody-labeled nontoxic polymer vesicles for cancer stem cells-targeted delivery of anticancer drug and siRNA. Biomacromolecules. 2015;16:1695–705.

Chen W, Yuan Y, Cheng D, Chen J, Wang L, Shuai X. Co-Delivery of doxorubicin and siRNA with reduction and pH dually sensitive nanocarrier for synergistic cancer therapy. Small. 2014;10:2678–87.

Chenthamara D, Subramaniam S, Ramakrishnan SG, Krishnaswamy S, Essa MM, Lin F-H, et al. Therapeutic efficacy of nanoparticles and routes of administration. Biomater Res. 2019;23(1):20.

Cherniakov I, Domb AJ, Hoffman A. Self-nano-emulsifying drug delivery systems: an update of the biopharmaceutical aspects. Expert Opin Drug Deliv 2015; 12:1121–33.

Chevalier R. siRNA targeting and treatment of gastrointestinal diseases. Clin Transl Sci. 2019;12: 573–85.

Crappo EF, Drago SE, Mauro N, Giammona G, Cavallaro G. Design of new polyaspartamide copolymers for siRNA delivery in antiasthmatic therapy. Pharmaceutics. 2020;12(2):89.

Cullis PR, Hope MJ. Lipid nanoparticle systems for enabling gene therapies. Mol Ther. 2017;25:1467–75.

Dalal L, Allaf AW, El-Zein H. Formulation and in vitro evaluation of self-nanoemulsifying liquid solid tablets of furosemide. Sci Rep. 2021;11(1):1315.

Dhiman N, Awasthi R, Sharma B, Kharkwal H, Kulkarni GT. Lipid nanoparticles as carriers for bioactive delivery. Front Chem. 2021;9:580118.

Dowaidar M, Abdelhamid HN, Hällbrink M, Freimann K, Kurrikoff K, Zou X, et al. Magnetic nanoparticle assisted self-assembly of cell penetrating peptides-oligonucleotides complexes for gene delivery. Sci Rep. 2017;7(1):9159.

El-Mayta R, Zhang R, Shepherd SJ, Wang F, Billingsley MM, Dutkin V, et al. A Nanoparticle platform for accelerated in vivo oral delivery screening of nucleic acids. Adv Ther. 2021;4(1):2000111.

Fairman K, Li M, Ning B, Lumen A. Physiologically based pharmacokinetic (PBPK) modeling of RNAi therapeutics: Opportunities and challenges. Biochem Pharmacol. 2021;189:114468.

Ferenczak K, Deitch I, Huckfeldt R. Antisense oligonucleotide therapy for ophthalmic conditions. Semin Ophthalmol. 2021;36:452–7.
Fliervoet LAL, Zhang H, van Groesen E, Fortuin K, Duin NJCB, Remaut K, et al. Local release of siRNA using polyplex-loaded thermosensitive hydrogels. Nanoscale. 2020;12:10347–60.

Fumoto S, Yamamoto T, Okami K, Maemura Y, Terada C, Yamayoshi A, et al. Understanding in vivo fate of nucleic acid and gene medicines for the rational design of drugs. Pharmaceuticals. 2021;13(2):159.

Gallon E, Matini T, Sasso L, Mantovani G, Armíañ G de Benito A, Sanchis J, et al. Triblock copolymer nanovesicles for pH-responsive targeted delivery and controlled release of siRNA to cancer cells. Biomacromolecules. 2015;16:1924–37.

Gao H, Cheng R, Santos HA. Nanoparticle-mediated siRNA delivery systems for cancer therapy. VIEW. 2021a;2(3):20200111.

Gao L, Yu S, Lin J, Chen S, Shen Z, Kang M. Construction of PD-L1-siRNA and IL-2 DNA loading PEI lipid nanoparticles in activating T cells and treating lung cancer. AIP Adv. 2021b;11(4):045201.

García-Fernández A, Sancenón F, Martínez-Máñez R. Mesoporous silica nanoparticles for pulmonary drug delivery. Adv Drug Deliv Rev. 2021;177:113953.

Ge X, Chen L, Zhao B, Yuan W. Rational and application of PEGylated lipid-based system for advanced target delivery of siRNA. Front Pharmacol. 2021;11:598175.

Ghezzi M, Pescina S, Padula C, Santi P, Del Favero E, Cantú L, et al. Polymeric micelles in drug delivery: An insight of the techniques for their characterization and assessment in biorelevant conditions. J Control Release. 2021;332:312–36.

Gidwani B, Sahu V, Shukla SS, Pandey R, Joshi V, Jain VK, et al. Quantum dots: Prospectives, toxicity, advances and applications. J Drug Deliv Sci Technol. 2021;61:102308.

Gilani SJ, Rizwanullah M, Imam SS, Pandit J, Aqil M, Alam M, et al. QbD considerations for topical and transdermal product development. In: Beg S, Hasnain MS: Pharmaceutical quality by design: principles and applications (pp 131-50). Amsterdam: Elsevier, 2019.

Gumala A, Suttiyo S. Active targeting gold nanoparticle for chemotherapy drug delivery: A Review. Pharm Sci. 2021; epub ahead of print. doi: 10.34172/PS.2021.75.

Habib S, Daniels A, Ariatti M, Singh M. Anti-c-myc cholesterol based lipplexes as onco-nanotherapeutic agents in vitro. F1000Res. 2021;9:770.

Han X, Zhang H, Butowska K, Swingle KL, Alameh M-G, Weissman D, et al. An ionizable lipid toolbox for RNA delivery. Nat Commun. 2021;12(1):7233.

Hanna K, Mayden K. The use of real-world evidence for oral chemotherapies in breast cancer. J Adv Pract Oncol. 2021;12(Suppl 2):13-20.

Hattori Y, Tamaki K, Sakasai S, Ozaki K, Onishi H. Effects of PEG anchors in PEGylated siRNA lipoplexes on in vitro gene-silencing effects and siRNA biodistribution in mice. Mol Med Rep. 2020;22:4183-96.

Hauptstein S, Prüfert F, Bernkop-Schnürch A. Self-nanoemulsifying drug delivery systems as novel approach for pDNA drug delivery. Int J Pharm. 2015;487:25–31.

He C, Liu D, Lin W. Self-assembled nanoscale coordination polymers carrying siRNAs and cisplatin for effective treatment of resistant ovarian cancer. Biomaterials. 2015;36:124–33.

He C, Yue H, Xu L, Liu Y, Song Y, Tang C, et al. siRNA release kinetics from polymeric nanoparticles correlate with RNAi efficiency and inflammation therapy via oral delivery. Acta Biomater. 2020;103: 213–22.

Hodgson J. Refreshing the biologic pipeline 2020. Nat Biotechnol. 2021;39:135–43.

Hosseini S, Wey K, Eppe M. Enteric coating systems for the oral administration of bioactive calcium phosphate nanoparticles carrying nucleic acids into the colon. ChemistrySelect. 2020;5(31):9720–9.

Huang R-Y, Liu Z-H, Weng W-H, Chang C-W. Magnetic nanocomplexes for gene delivery applications. J Mater Chem B. 2021;9:4267–86.

Ibaraki H, Kanazawa T, Owada M, Iwaya K, Takashima Y, Seta Y. Anti-metastatic effects on melanoma via intravenous administration of anti-NF-κB siRNA complexed with functional peptide-modified nano-micelles. Pharmaceutics. 2020;12(1): 64.

Inglut CT, Sorrin AJ, Kuruppu T, Vig S, Cicalo J, Ahmad H, et al. Immunological and toxicological considerations for the design of liposomes. Nanomaterials. 2020;10(2):190.

Iqbal S, Blenner M, Alexander-Bryant A, Larsen J. Polymersomes for therapeutic delivery of protein and nucleic acid macromolecules: from design to therapeutic applications. Biomacromolecules. 2020;21:1327–50.
Itani R, Al Faraj A. siRNA conjugated nanoparticles - a next generation strategy to treat lung cancer. Int J Mol Sci. 2019;20(23):6088.

Jain V, Kumar H, Chand P, Jain S, S P. Lipid-based nanocarriers as drug delivery system and its applications. In: Dave V, Gupta N, Sur S (eds): Nanopharmaceutical advanced delivery systems (pp 1-29). Beverly, MA: Scriverene Publishing LLC. 2021.

Jiang Z, Thayumanavan S. Noncationic material design for nucleic acid delivery. Adv Ther. 2020;3(3):1900206.

Jyotsana N, Sharma A, Chaturvedi A, Budida R, Scherr M, Kuchenbauer F, et al. Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo. Ann Hematol. 2019;98:1905–18.

Kala S, Mak ASC, Liu X, Posocco P, Pricl S, Peng L, et al. Combination of dendrimer-nanovector-mediated small interfering RNA delivery to target akt with the clinical anticancer drug paclitaxel for effective and potent anticancer activity in treating ovarian cancer. J Med Chem. 2014;57:2634–42.

Kaneshiro TL, Lu Z-R. Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. Biomaterials. 2009;30:5660–6.

Kanugo A, Misra A. New and novel approaches for enhancing the oral absorption and bioavailability of protein and peptides therapeutics. Ther Deliv. 2020;11:713–32.

Khalid K, Tan X, Mohd Zaid HF, Tao Y, Lye Chew C, Chu D-T, et al. Advanced in developmental organic and inorganic nanomaterials: a review. Bioengineered. 2020;11:328–55.

Khan MA, Singh D, Ahmad A, Siddique HR. Revisiting inorganic nanoparticles as promising therapeutic agents: A paradigm shift in oncological theranostics. Eur J Pharm Sci. 2021;164:105892.

Khurana A, Tekula S, Saifi MA, Venkatesh P, Godugu C. Therapeutic applications of selenium nanoparticles. Biomed Pharmacother. 2019;111:802–12.

Kim B, Park J, Sailor MJ. Rekindling RNAi therapy: materials design requirements for in vivo siRNA delivery. Adv Mater. 2019a;31(49):1903637.

Kim H-O, Kim E, An Y, Choi J, Jang E, Choi EB, et al. A biodegradable polymersome containing bcl-xl siRNA and doxorubicin as a dual delivery vehicle for a synergistic anticancer effect. Macromol Biosci. 2013;13:745–54.

Kim MW, Jeong HY, Kang SJ, Choi MJ, You YM, Im CS, et al. Cancer-targeted nucleic acid delivery and quantum dot imaging using EGF receptor aptamer-conjugated lipid nanoparticles. Sci Rep. 2017;7(1):9474.

Kim MW, Jeong HY, Kang SJ, Jeong IH, Choi MJ, You YM, et al. Anti-EGF receptor aptamer-guided co-delivery of anti-cancer siRNAs and quantum dots for theranostics of triple-negative breast cancer. Theranostics. 2019b;9:837–52.

Kim Y, Tewari M, Pajerowski DJ, Cai S, Sen S, Williams J, et al. Polymersome delivery of siRNA and antisense oligonucleotides. J Control Release. 2009;134:132–40.

Kim YH, Lee K, Li S. Nucleic acids based polyelectrolyte complexes: their complexation mechanism, morphology, and stability. Chem Mater. 2021;33:7923–43.

Knaub K, Sartorius T, Dharsono T, Wacker R, Wilhelm M, Schön C. A novel self-emulsifying drug delivery system (SEDDS) based on VESIsorb® formulation technology improving the oral bioavailability of cannabidiol in healthy subjects. Molecules. 2019;24(16):2967.

Kokkinos J, Ignacio RMC, Sharbeen G, Boyer C, Gonzales-Aloy E, Goldstein D, et al. Targeting the undruggable in pancreatic cancer using nano-based gene silencing drugs. Biomaterials. 2020;240:119742.

Koytova R, Caffrey M. Phases and phase transitions of the phosphatidylcholines. Biochim Biophys Acta. 1998;1376:91–145.

Krstić M, Medarević D, Đuriš J, Ibrić S. Self-emulsifying drug delivery systems (SNEDDS) and self-microemulsifying drug delivery systems (SMEDDS) as lipid nanocarriers for improving dissolution rate and bioavailability of poorly soluble drugs. In: Grumezescu AM (ed): Lipid nanoparticles as drug delivery system and its applications. Amsterdam: Elsevier, 2018.

Kubackova J, Holas O, Zbytovska J, Vranikova B, Zeng G, Pavek P, et al. Oligonucleotide delivery across the Caco-2 monolayer: the design and evaluation of self-emulsifying drug delivery systems (SEDDS). Pharmaceutics. 2021;13(4):459.

Lee D-J, Kessel E, Edinger D, He D, Klein PM, Voith von Voithenberg L, et al. Dual antitumoral potency of EG5 siRNA nanoplexes armed with cytotoxic bifunctional glutamyl-methotrexate targeting ligand. Biomaterials. 2016;77:98–110.
Majumder J, Minko T. Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery. Expert Opin Drug Deliv. 2021;18:205–27.

Maurer V, Altin S, Ag Selei D, Zarinwall A, Temel B, Vogt PM, et al. In-vitro application of magnetic hybrid niosomes: targeted siRNA-delivery for enhanced breast cancer therapy. Pharmaceutics. 2021;13(3):394.

Mehanna MM, Mmeimneh AT. Formulation and applications of lipid-based nanovehicles: spotlight on self-emulsifying systems. Adv Pharm Bull. 2020;11(1):56–67.

Meng H, Lione M, Xia T, Li Z, Ji Z, Zink JI, et al. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and p-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano. 2010;4:4539–50.

Misra R, Das M, Sahoo BS, Sahoo SK. Reversal of multidrug resistance in vitro by co-delivery of MDR1 targeting siRNA and doxorubicin using a novel cationic poly(lactide-glycolide) nanoformulation. Int J Pharm. 2014;475:372–84.

Moore JA, Chow JCL. Recent progress and applications of gold nanotechnology in medical biophysics using artificial intelligence and mathematical modeling. Nano Express. 2021;2(2):022001.

Morakul B. Self-nanoemulsifying drug delivery systems (SNEDDS): an advancement technology for oral drug delivery. Pharm Sci Asia. 2020;47:205–20.

Moulahom H, Ghorbanizamani F, Zihnoiulu F, Timur S. Surface biomodification of liposomes and polymersomes for efficient targeted drug delivery. Bioconj Chem. 2021;32:1491–502.

Mousazadeh H, Pilehvar-Soltanahmadi Y, Dadashpour M, Zarghami N. Cyclodextrin based natural nanostructured carbohydrate polymers as effective non-viral siRNA delivery systems for cancer gene therapy. J Control Release. 2021;330:1046–70.

Ng N, Rogers MA. Surfactants. In: Melton L, Shahidi F, Varelis P (eds): Encyclopedia of food chemistry, Vol. 1 (pp 276–82). Amsterdam: Elsevier, 2019.

Noh SM, Han SE, Shim G, Lee KE, Kim C-W, Han SS, et al. Tocopheryl oligochitosan-based self assembling oligomersomes for siRNA delivery. Biomaterials. 2011;32:849–57.

Noske S, Karimov M, Aigner A, Ewe A. Tyrosine-modification of polypropylenimine (PPI) and polyethyl- ylenimine (PEI) strongly improves efficacy of siRNA-mediated gene knockdown. Nanomaterials. 2020;10(9):1809.
Ojo OA, Olayide II, Akalabu MC, Ajiboye BO, Ojo AB, Oyinloye BE, et al. Nanoparticles and their biomedical applications. Biointerface Res Appl Chem. 2021;11:8431–45.

Okonogi S, Phumat P, Khongkhunthian S, Chaijareenont P, Rades T, Müllertz A. Development of self-nanoemulsifying drug delivery systems containing 4-allylpyrocatechol for treatment of oral infections caused by Candida albicans. Pharmaceutics. 2021;13 (2):167.

Pan J, Mendes LP, Yao M, Filipczak N, Garai S, Thakur GA, et al. Polyamidoamine dendrimer-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance. Eur J Pharm Biopharm. 2019;136:18–28.

Pandey A. Cyclodextrin-based nanoparticles for pharmaceutical applications: a review. Environ Chem Lett. 2021;19:4297–310.

Pandey M, Rani P, Adhikari L, Gupta M, Semalty A, Semalty M. Preparation and characterization of cyclodextrin complexes of doxycycline hyclate for improved photostability in aqueous solution. J Incl Phenom Macrocycl Chem. 2022;102:271–8.

Pangburn TO, Georgiou K, Bates FS, Kokkoli E. Targeted polymersome delivery of siRNA induces cell death of breast cancer cells dependent upon Orai3 protein expression. Langmuir. 2012;28:12816–60.

Patel P, Ibrahim NM, Cheng K. The importance of apparent pKa in the development of nanoparticles encapsulating siRNA and mRNA. Trends Pharmacol Sci. 2021;42:448–60.

Paunovska K, Loughrey D, Dahlman JE. Drug delivery systems for RNA therapeutics. Nat Rev Genet. 2022;23:265-80.

Petitjean M, García-Zubiri IX, Isasi JR. History of cyclodextrin-based polymers in food and pharmacy: a review. Environ Chem Lett. 2021;19:3465–76.

Pishavvar E, Oroojalian F, Salmasi Z, Hashemi E, Hashemi M. Recent advances of dendrimer in targeted delivery of drugs and genes to stem cells as cellular vehicles. Biotechnol Prog. 2021;37(4):e3174.

Plaza-Óliver M, Santander-Ortega MJ, Lozano MV. Current approaches in lipid-based nanocarriers for oral drug delivery. Drug Deliv Transl Res. 2021;11:471–97.

Pylaev T, Avdeeva E, Khlebtsov N. Plasmonic nanoparticles and nucleic acids hybrids for targeted gene delivery, bioimaging, and molecular recognition. J Innov Opt Health Sci. 2021;14(04):2130003.

Qiao H, Zhang L, Fang D, Zhu Z, He W, Hu L, et al. Surmounting tumor resistance to metallo drugs by co-loading a metal complex and siRNA in nanoparticles. Chem Sci. 2021;12:4547–56.

Qu M, Ouyang J, Wei Y, Zhang J, Lan Q, Deng C, et al. Selective cell penetrating peptide – functionalized envelope – type chimeric lipopeosomes boost systemic RNAi therapy for lung tumors. Adv Healthc Mater. 2019;8(16):1900500.

Qu M-H, Zeng R-F, Fang S, Dai Q-S, Li H-P, Long J-T. Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer. Int J Pharm. 2014;474:112–22.

Rehman AU, Akram S, Seralin A, Vandamme T, Anton N. Lipid nanocarriers: Formulation, properties, and applications. In: Nguyen-Tri P, Do T-O, Nguyen TA (eds): Smart nanocontainers. A volume in micro and nano technologies (pp 355-82). Amsterdam: Elsevier, 2020.

Rehman AU, Busignies V, Coelho Silva Ribeiro M, Almeida Lage N, Tchoreloff P, Escriou V, et al. Fate of tableted freeze-dried siRNA lipoplexes in gastrointestinal environment. Pharmaceutics. 2021;13 (11):1807.

Rehman FU, Shah KU, Shah SU, Khan IU, Khan GM, Khan A. From nanoemulsions to self-nanoemulsions, with recent advances in self-nanoemulsifying drug delivery systems (SNEDDS). Expert Opin Drug Deliv. 2017;14:1325–40.

Ruiz-Picazo A, Lozoya-Agullo I, González-Álvarez I, Bermejo M, González-Álvarez M. Effect of excipients on oral absorption process according to the different gastrointestinal segments. Expert Opin Drug Deliv. 2021;18:1005–24.

Sajid MI, Moazzam M, Kato S, Yeseom Cho K, Tiwari RK. Overcoming barriers for siRNA therapeutics: from bench to bedside. Pharmaceuticals. 2020;13(10):294.

Salzano G, Navarro G, Trivedi MS, De Rosa G, Torchilin VP. Multifunctional polymeric micelles co-loaded with anti-surivivin siRNA and paclitaxel overcome drug resistance in an animal model of ovarian cancer. Mol Cancer Ther. 2015;14:1075–84.

Sánchez-Arribas N, Martínez-Negro M, Villar EM, Pérez L, Osío Barcina J, Ai cA cT E, et al. Protein expression knockdown in cancer cells induced by a gemini cationic lipid nanovector with histidine-based polaronic heads. Pharmaceutics. 2020;12(9):791.

Sarkies P, Miska EA. Small RNAs break out: the molecular cell biology of mobile small RNAs. Nat Rev Mol Cell Biol. 2014;15:525–35.
Scheerstra JF, Wauters AC, Tel J, Abdelmohsen LKEA, van Hest JCM. Polymersomes as a potential platform for cancer immunotherapy. Mater Today Adv. 2022;13:100203.

Scheideler M, Vidakovic I, Prassl R. Lipid nanocarriers for microRNA delivery. Chem Phys Lipids. 2020;226:104837.

Shahabani E, Sharifiaghdam M, De Keersmaecker H, De Rycke R, De Smiedt S, Faridi-Majidi R, et al. Layer by layer assembled chitosan-coated gold nanoparticles for enhanced siRNA delivery and silencing. Int J Mol Sci. 2021;22(2):831.

Sharma A, Jha NK, Daihy K, Singh VK, Chaurasiya K, Jha AN, et al. Nanoparticulate RNA delivery systems in cancer. Cancer Rep (Hoboken). 2020;3(5):e1271.

Shi K, Zhao Y, Miao L, Satterlee A, Haynes M, Luo C, et al. Dual functional lipomet mediates envelope-type nanoparticles to combinational oncogene silencing and tumor growth inhibition. Mol Ther. 2017;25:1567–79.

Shin JH, Shin DH, Kim JS. Let-7 miRNA and CDK4 siRNA co-encapsulated in Herceptin-conjugated liposome for breast cancer stem cells. Asian J Pharm Sci. 2020;15:472–81.

Singh A, Trivedi P, Jain NK. Advances in siRNA delivery in cancer therapy. Artif Cells Nanomed Biotechnol. 2018;46:274-83.

Singh A, Mallika TN, Gorain B, Yadav AK, Tiwari S, Flora SJS, et al. Quantum dot: Heralding a brighter future in neurodegenerative disorders. J Drug Deliv Sci Technol. 2021;65:102700.

Smith SA, Selby LI, Johnston APR, Such GK. The endosomal escape of nanoparticles: toward more efficient cellular delivery. Bioconjug Chem. 2019;30:263–72.

Sokkula SR, Gande S. A comprehensive review on self-nano-emulsifying drug delivery systems: advancements & applications. Int J Pharm Sci Drug Res. 2020;12:576–83.

Subhan MA, Attia SA, Torchilin VP. Advances in siRNA delivery strategies for the treatment of MDR cancer. Life Sci. 2021;274:119337.

Sun T-M, Du J-Z, Yao Y-D, Mao C-Q, Dou S, Huang S-Y, et al. Simultaneous delivery of siRNA and paclitaxel via a “two-in-one” micelleplex promotes synergistic tumor suppression. ACS Nano. 2011;5:1483–94.

Taleghani AS, Nakhjiri AT, Khakzad MJ, Rezayat SM, Ebrahimmnejad P, Heydarinasab A, et al. Mesoporous silica nanoparticles as a versatile nanocarrier for cancer treatment: A review. J Mol Liq. 2021;328:115417.

Tandale P, Choudhary N, Singh J, Sharma A, Shukla A, Sriram P, et al. Fluorescent quantum dots: An insight on synthesis and potential biological application as drug carrier in cancer. Biochem Biophys Reports. 2021;26:100962.

Tang S, Yin Q, Su J, Sun H, Meng Q, Chen Y, et al. Inhibition of metastasis and growth of breast cancer by pH-sensitive poly (β-amino ester) nanoparticles co-delivering two siRNA and paclitaxel. Biomaterials. 2015;48:1–15.

Taschauer A, Polzer W, Pöschl S, Metz S, Tepe N, Decker S, et al. Combined chemisorption and complexation generate siRNA nanocarriers with biophysics optimized for efficient gene knockdown and air–blood barrier crossing. ACS Appl Mater Interfaces. 2020;12:30095–111.

Tenchov R, Bird R, Curtze AE, Zhou Q. Lipid nanoparticles - from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano. 2021;15:16982–7015.

Torres-Vanegas JD, Cruz JC, Reyes LH. Delivery systems for nucleic acids and proteins: barriers, cell capture pathways and nanocarriers. Pharmaceutics. 2021;13(3):428.

Tran P, Park J-S. Recent trends of self-emulsifying drug delivery system for enhancing the oral bioavailability of poorly water-soluble drugs. J Pharm Investig. 2021;51:439–63.

Tran T, Rades T, Mülertz A. Formulation of self-nanoemulsifying drug delivery systems containing monoacetyl phosphatidylcholine and Kolliphor® RH40 using experimental design. Asian J Pharm Sci. 2018;13:536–45.

van den Berg AIS, Yun C-O, Schiffelers RM, Hennink WE. Polymeric delivery systems for nucleic acid therapeutics: Approaching the clinic. J Control Release. 2021;331:121–41.

van den Brand D, Mertens V, Massuger LFAG, Brock R. siRNA in ovarian cancer – Delivery strategies and targets for therapy. J Control Release. 2018;283:45–58.

Vasile C. Polymeric nanomaterials. In: Vasile C (ed): Polymeric nanomaterials in nanotherapeutics (pp 1-66). Amsterdam: Elsevier, 2019.

Wan Z, Zheng R, Moharil P, Liu Y, Chen J, Sun R, et al. Polymeric micelles in cancer immunotherapy. Molecules. 2021;26(5):1220.
Wang D, Xu X, Zhang K, Sun B, Wang L, Meng L, et al. Codelivery of doxorubicin and MDR1-siRNA by mesoporous silica nanoparticles-polymer-polyethyleneimine to improve oral squamous carcinoma treatment. Int J Nanomedicine. 2017;13:187–98.

Wang F, Gao J, Xiao J, Du J. Dually grafted polymersomes for gene delivery. Nano Lett. 2018;18:5562–8.

Wang X, Zhang M, Woloshun RR, Yu Y, Lee JK, Flores SRL, et al. Oral administration of ginger-derived lipid nanoparticles and Dmt1 siRNA potentiates the effect of dietary iron restriction and mitigates pre-existing iron overload in Hamp KO mice. Nutrients. 2021;13(5):1686.

Wen Y, Bai H, Zhu J, Song X, Tang G, Li J. A supramolecular platform for controlling and optimizing molecular architectures of siRNA targeted delivery vehicles. Sci Adv. 2020;6(31):eabc2148.

Witika BA, Makoni PA, Matafwali SK, Chabalenge B, Mwila C, Kalungia AC, et al. Biocompatibility of biomaterials for nanoencapsulation: Current Approaches. Nanomaterials. 2020;10(9):1649.

Xiong X-B, Lavasanifar A. Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. ACS Nano. 2011;5:5202–13.

Xu C, Yu B, Qi Y, Zhao N, Xu F. Versatile types of cyclodextrin-based nucleic acid delivery systems. Adv Healthc Mater. 2021a;10(1):2001183.

Xu X, Xie K, Zhang X-Q, Bridgen EM, Park GY, Cui DS, et al. Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug. Proc Natl Acad Sci. 2013;110:18638–43.

Xu Y, Michalowski CB, Beloqui A. Advances in lipid carriers for drug delivery to the gastrointestinal tract. Curr Opin Colloid Interface Sci. 2021b;52:101414.

Xue C, Hu S, Gao Z-H, Wang L, Luo M-X, Yu X, et al. Programmably tiling rigidified DNA brick on gold nanoparticle as multi-functional shell for cancer-targeted delivery of siRNAs. Nat Commun. 2021a;12(1):2928.

Xue X, Li J, Fan Y, Shen M, Shi X. Gene silencing-mediated immune checkpoint blockade for tumor therapy boosted by dendrimer-entrapped gold nanoparticles. Sci China Mater. 2021b;64:2045–55.

Yan X, Yang Y, Sun Y. Dendrimer applications for cancer therapies. J Phys Conf Ser. 2021;1948(1):012205.
Zou Y, Zheng M, Yang W, Meng F, Miyata K, Kim HJ, et al. Virus-mimicking chimaeric polymersomes boost targeted cancer siRNA therapy in vivo. Adv Mater. 2017;29(42):1703285.

Zu M, Ma Y, Cannup B, Xie D, Jung Y, Zhang J, et al. Oral delivery of natural active small molecules by polymeric nanoparticles for the treatment of inflammatory bowel diseases. Adv Drug Deliv Rev. 2021;176:113887.